Payment overview · 2025
General Payments
$290.10
15 reported records · 13 companies
Healthcare provider profile · identity verified
Fernando Garcia, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MARKSVILLE, LA · NPI 1992707236
Verified facts
What the public records show
CMS Open Payments records show Fernando Garcia, M.D. received $290.10 in general payments during 2025 across 15 reported records.
Lilly USA, LLC accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.72 | 14.4% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $35.12 | 12.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.15 | 8.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.23 | 8.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $21.81 | 7.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.65 | 7.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.06 | 7.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.85 | 6.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.70 | 6.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.64 | 6.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.86 | 5.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.53 | 5.0% | 1 | 2025 |
| AYTU BioPharma, Inc. | Unresolved — no canonical attribution shown | $13.78 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $290.10 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| Karbinal Normalized: karbinal |
Drug | AYTU BioPharma, Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 61 |
| Gabapentin | Gabapentin | 267 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 58 |
| Eliquis | Apixaban | 209 | 19 |
| Furosemide | Furosemide | 194 | 41 |
| Metformin Hcl | Metformin Hcl | 188 | 43 |
| Lisinopril | Lisinopril | 184 | 38 |
| Potassium Chloride | Potassium Chloride | 165 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 161 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 157 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 156 | 28 |
| Omeprazole | Omeprazole | 150 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 27 |
| Jardiance | Empagliflozin | 121 | 14 |
| Losartan Potassium | Losartan Potassium | 113 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 28 |
| Carvedilol | Carvedilol | 92 | 15 |
| Ozempic | Semaglutide | 84 | 16 |
| Montelukast Sodium | Montelukast Sodium | 80 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 15 |
| Mirtazapine | Mirtazapine | 68 | suppressed |
| Trulicity | Dulaglutide | 68 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 14 |
| Trazodone Hcl | Trazodone Hcl | 67 | 12 |
| Alprazolam | Alprazolam | 65 | 11 |
| Meloxicam | Meloxicam | 61 | 16 |
| Tramadol Hcl | Tramadol Hcl | 60 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 15 |
| Sucralfate | Sucralfate | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 12 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Glipizide | Glipizide | 52 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 11 |
| Ezetimibe | Ezetimibe | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | suppressed |
| Simvastatin | Simvastatin | 40 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 37 | suppressed |
| Azithromycin | Azithromycin | 35 | 29 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 19 |
| Allopurinol | Allopurinol | 33 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Prednisone | Prednisone | 28 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Nystatin | Nystatin | 23 | 12 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Phenytoin | Phenytoin | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $290.10 · 15 records | Lilly USA, LLC | AIRSUPRA, AUSTEDO XR, Auvelity, CAPLYTA, COBENFY, Cologuard Collection Kit, EVENITY, IBSRELA, Karbinal, MOUNJARO, Ozempic, QULIPTA, REXULTI, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error